ABIVAX Société Anonyme

NasdaqGM:ABVX Stock Report

Market Cap: US$10.5b

ABIVAX Société Anonyme Future Growth

Future criteria checks 5/6

ABIVAX Société Anonyme is forecast to grow earnings and revenue by 67% and 58.6% per annum respectively. EPS is expected to grow by 53.9% per annum. Return on equity is forecast to be -238% in 3 years.

Key information

67.0%

Earnings growth rate

53.90%

EPS growth rate

Biotechs earnings growth25.4%
Revenue growth rate58.6%
Future return on equity-237.95%
Analyst coverage

Good

Last updated26 May 2026

Recent future growth updates

No updates

Recent updates

Seeking Alpha • Apr 01

Abivax: Obefazimod's Strategic Scarcity Drives Optionality (Maintaining Buy)

Summary Abivax remains a buy, with Obefezimod showing best-in-class efficacy and safety in ulcerative colitis and potential in Crohn’s disease. Updated phase 3 and UEG safety data further de-risk ABVX, supporting earlier line use and expanding market potential beyond refractory patients. I raise my probability of success to 95%, increasing the 12-month target price to $140 per share, reflecting ~25% upside. Key catalysts include Q2 2026 maintenance data and 2H 2026 NDA/MAA filings, with M&A potential as a significant upside driver. Read the full article on Seeking Alpha
Seeking Alpha • Mar 27

ABIVAX: Undercovered, Late-Stage French Company With Upcoming Catalysts

Summary ABIVAX is a French company that IPO-ed in the US in 2023 and is running a phase 3 trial for ulcerative colitis. Their lead candidate, obefazimod, is in phase 3 trials for moderate to severe ulcerative colitis and has a novel mechanism of action. The company faces competition from other approved treatments for ulcerative colitis, but their drug has shown promising efficacy and a good safety profile. Read the full article on Seeking Alpha

Earnings and Revenue Growth Forecasts

NasdaqGM:ABVX - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202842818-27-359
12/31/2027118-183-69-7314
12/31/20264-242-240-23511
3/31/20265-332-179-178N/A
12/31/20255-336-161-161N/A
9/30/20257-294-172-171N/A
6/30/20258-195-136-136N/A
3/31/202512-186-153-153N/A
12/31/202412-176-155-154N/A
9/30/20249-185-156-155N/A
6/30/20249-177-155-155N/A
3/31/20245-165-118-118N/A
12/31/20235-148-97-97N/A
9/30/20235-120-77-77N/A
6/30/20234-92-57-57N/A
3/31/20234-76-56-55N/A
12/31/20225-61-54-54N/A
9/30/20228-54N/AN/AN/A
6/30/20222-47-46-46N/A
3/31/20221-45-46-46N/A
12/31/20214-42-45-45N/A
9/30/20210-41N/AN/AN/A
6/30/20210-39-46-45N/A
3/31/20210-38-38-38N/A
12/31/20200-38-31-30N/A
9/30/20200-35N/AN/AN/A
6/30/20200-32-25-24N/A
3/31/20200-31-27-26N/A
12/31/20190-31N/A-27N/A
9/30/20190-27N/A-22N/A
6/30/20190-23N/A-17N/A
3/31/20191-19N/A-16N/A
12/31/20181-16N/A-15N/A
9/30/20181-14N/A-13N/A
6/30/20181-13N/A-11N/A
3/31/20181-12N/A-10N/A
12/31/20170-11N/A-8N/A
9/30/20170-11N/AN/AN/A
6/30/20170-12N/A-11N/A
3/31/20170-13N/A-14N/A
12/31/20160-14N/A-16N/A
9/30/20160-16N/AN/AN/A
6/30/20160-17N/A-24N/A
3/31/20160-17N/A-19N/A
12/31/20150-16N/A-15N/A
9/30/20150-14N/AN/AN/A
6/30/20150-12N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABVX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.5%).

Earnings vs Market: ABVX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ABVX is expected to become profitable in the next 3 years.

Revenue vs Market: ABVX's revenue (58.6% per year) is forecast to grow faster than the US market (11.9% per year).

High Growth Revenue: ABVX's revenue (58.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ABVX is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/01 20:02
End of Day Share Price 2026/05/29 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ABIVAX Société Anonyme is covered by 21 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Etzer DaroutBarclays
Julian HarrisonBTIG
Jason ButlerCitizens JMP Securities, LLC